Drug intelligence / Profile preview

smp-3124lp

Development stage: Phase 2
Lead developer: Sumitomo Pharma America
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

SMP-3124LP is a liposomal formulation of an inhibitor targeting checkpoint kinase 1 (Chk1), developed for the treatment of advanced solid tumors. By inhibiting Chk1, a key regulator in the DNA damage response and cell cycle control, this agent aims to disrupt tumor cell repair mechanisms and enhance chemosensitization. The drug is currently being evaluated in phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in adults with advanced solid tumors[3][6]. The use of a liposomal delivery system may improve drug stability and tumor targeting.

Other names: liposomal Chk1 inhibitor SMP-3124liposomal Chk1 inhibitor SMP-3124LP

Targets

CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on smp-3124lp.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on smp-3124lp.

Explore the full profile